Peptide Receptor Radionuclide Therapy in 58 Patients With Differentiated Thyroid Carcinoma
| References | Tumor classification | Radiopharmaceutical | Cumulative dose | Response (TTP [mo]) | Criteria* | ||||
|---|---|---|---|---|---|---|---|---|---|
| Radionuclide | Chelator | Peptide | |||||||
| Gorges et al., 2001 (14) | 3 × HCTC | 90Y | DOTA | 1.7–9.6 GBq | 1 × SD (21), 2 × PD | NA | |||
| Waldherr et al., 2001 (15) | 3 × FTC; 4 × PTC; 1 × ATC | 90Y | DOTA | 1.7–14.8 GBq | 2 × SD (8,8); 6 × PD | WHO | |||
| Virgolini et al., 2002 (16) | 25 × TC | 90Y | DOTA | Lanreotide | 0.9–7.0 GBq | 3 × RD (NA), 11 × SD (NA), 11 × PD | WHO | ||
| Valkema et al., 2002 (17) | 1 × FTC; 4 × PTC | 111ln | DTPA | Octreotide | 3.0–8.3 GBq | 4 × PD; 1 × SD | SWOG | ||
| Chinol et al., 2002 (21) | 2 × PTC | 90Y | DOTA | >7.4 GBq | SWOG | ||||
| Christian et al., 2003 (12) | 1 × HCTC | 90Y | DOTA | NA | |||||
| Gabriel et al., 2004 (24) | 4 × FTC; 1 × PTC | 90Y | DOTA | 5.6–7.4 GBq | 5 × SD (5) | NA | |||
| Stokkel et al., 2004 (23) | 4 × FTC; 5 × PTC | 111ln | DTPA | Octreotide | 14.3–33.1 GBq | 4 × SD; 5 × PD | NA | ||
↵* WHO = World Health Organization criteria: regressive disease = >25% reduction in tumor size; SD = <25% reduction or increase in tumor size; PD = >25% increase in tumor size. SWOG = Southwest Oncology Group criteria of tumor response: PR = >50% reduction in tumor size; SD = ±25% reduction or increase in tumor size; PD = >25% increase in tumor size.
TC = undefined thyroid cancer; ATC = anaplastic thyroid carcinoma; NA = not available.